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osting by EAbstract Reaction of 5-ethyl pyridine-2-ethanol 1 and methane sulphonyl chloride gives corre-
sponding sulphonate 2; which on condensation with p-hydroxy benzaldehyde will give 4-[2-(5-eth-
ylpyridin-2-yl)ethoxy]benzaldehyde 3. A series of chalcones 4a–o were prepared from 3 and
substituted aromatic acetophenone. Chalcones 4a–o further react with guanidine nitrate to give a
series of pyrimidines 5a–o which condense with 3,4-dichlorobenzylchloride to give amide derivatives
6a–o. Newly synthesized compounds have been examined on the basis of spectral analysis. All the
compounds were screened against different gram-positive and gram-negative bacteria. Most of
these compounds showed better inhibitory activity in comparison with the standard drugs.
ª 2010 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
The number of life-threatening infections caused by multidrug-
resistant gram-positive pathogens has reached an alarming
level in hospitals and community. Infections caused by these
organisms pose a serious challenge to the scientiﬁc community261 2264746; fax: +91 0261
n (N.B. Patel).
y. Production and hosting by
Saud University.
lsevierand the need for an effective therapy has led to a search for
novel antibacterial agents.
Amides, thioamides and carbamates are versatile intermedi-
ates in the synthesis of natural products. A large number of
antibiotics contain amide linkage. Several derivatives of
amides were prepared and found to possess different activities
like antimicrobial (Aytemir et al., 2003; Yildiz Oren et al.,
2004; Temiz-Arpacı et al., 2005) antibacterial (Desai and Chi-
khalia, 2005) antifungal, antimycobacterial activities and pho-
tosynthesis inhibition activity (Dolezal et al., 2002, 2006).
Amide also possessed anti-inﬂammatory and analgesic activi-
ties (Zhong et al., 2009; Banoglu et al., 2007; Geronikaki
et al., 2003). Several amides also displayed brain antihypoxic
activity (Mitkov et al., 2007), antinociceptive (Onkol et al.,
2004) and insecticidal activity (De Paula et al., 2000).
Literature survey reveals that various drugs for e.g. penicil-
lin, pyrazinamide, indinavir, and ritonavir contain particular
activities due to the amide linkage present in their structures.
The present study is concerned with the synthesis of the ser-
ies of heterocyclic amides prepared from pyrimidine deriva-




Laboratory Chemicals were supplied by Rankem India Ltd.
and Ficher Scientiﬁc Ltd. Melting points were determined by
the open tube capillary method and are uncorrected. The purity
of the compounds was determined by thin layer chromatogra-
phy (TLC) plates (silica gel G) in the toluene:ethyl acetate
(7.5:2.5) solvent system. The spots were observed by exposure
to iodine vapours or by UV light. The IR spectra were obtained
on a Perkin–Elmer 1720 FT-IR spectrometer (KBr pellets). The
1H NMR and 13C NMR spectra were recorded on a Bruker
Avance II 400 spectrometer using TMS as the internal standard
in CDCl3. Elemental analysis of the newly synthesized com-
pounds was carried out on a Carlo Erba 1108 analyzer.
2.2. General preparation of the compounds 4a–o
To a solution of 3 (4-[2-(5-ethylpyridin-2-yl)ethoxy]benzalde-
hyde) (Gaonkar et al., 2006; Momose et al., 1991) (0.01 mol)
in methanol (50 mL), different substituted aromatic acetophe-
nones (0.01 mol) were added in the presence of 2% NaOH
solution (5 mL) and the mixtures were stirred for 10–12 h at
room temperature. The solvent was distilled off and crude
product poured into ice water. The compound thus obtained
was washed with water and recrystallized from ethanol to get
the pure intermediate (Fig. 1).
2.2.1. 5-Ethyl-2-{[4-(1-(2,4-dichloro-5-ﬂuorophenyl)-2-propan-
1-one-3-yl)]phenoxy ethyl} pyridine (4a)
m.p. 121–123 C. Yield 80%. Rf: 0.58. IR (KBr): t= 3062
(Ar-H), 2953, 2836 (–CH2–), 1664 (–C‚O), 1598(–
CH‚CH–), 1223, 1033 (C–O–C), 975 (C–F), 742 (C–Cl). 1H
NMR (CDCl3, 400 MHz): d= 1.17 (t, 3H, –CH3), 2.54 (q,
2H, –CH2), 3.16 (t, 2H, –CH2), 4.32 (t, 2H, –CH2–O), 7.00–
7.84 (m, 6H, Ar–H), 7.10 (d, 1H, ‚CH–CO), 7.18 (d, 1H, –
CH), 7.36–8.28 (m, 3H, Pyridine-H); 13C NMR (100 MHz,
CDCl3): d= 15.5 (C-8), 25.1 (C-7), 38.0 (C-9), 67.5 (C-10),
115.5–156.0 (C-11–C-16), 117.3–161.5 (C-20–C-25), 119.2 (C-
18), 122.4–160.5 (C-2–C-6), 144.5 (C-17), 190.5 (C-19). Anal.




m.p. 84–86 C. Yield 72%. Rf: 0.56. IR (KBr): t= 3064 (Ar-





























Figure 1 Chalcones 4a–o.1220, 1028 (C–O–C). 1H NMR (CDCl3, 400 MHz): d= 1.19
(t, 3H, –CH3), 2.57 (q, 2H, –CH2), 3.19 (t, 2H, –CH2), 3.84
(s, 3H, –OCH3), 4.33 (t, 2H, –CH2–O), 7.12 (d, 1H, ‚CH–
CO), 7.20 (d, 1H, –CH), 7.38–8.27 (m, 3H, Pyridine-H),
7.05–8.11 (m, 8H, Ar-H); 13C NMR (100 MHz, CDCl3):
d= 15.3 (C-8), 25.5 (C-7), 37.0 (C-9), 55.5 (C-26), 66.4 (C-
10), 115.0–116.4 (C-20–C-25), 115.2–155.5 (C-11–C-16),
118.5 (C-18), 124.0–160.0 (C-2–C-6), 143.5 (C-17), 189.5 (C-




m.p. 95–97 C.Yield 82%.Rf: 0.54. IR (KBr): t= 3066 (Ar-H),
2953, 2835 (–CH2–), 1660 (–C‚O), 1592 (–CH‚CH–), 1218,
1030 (C–O–C), 740 (C–Cl). 1H NMR (CDCl3, 400 MHz):
d= 1.18 (t, 3H, –CH3), 2.56 (q, 2H, –CH2), 3.18 (t, 2H, –
CH2), 4.35 (t, 2H, –CH2–O), 7.03–7.69 (m, 7H, Ar-H), 7.13 (d,
1H, ‚CH–CO), 7.17 (d, 1H, –CH), 7.39–8.29 (m, 3H, Pyri-
dine-H); 13C NMR (100 MHz, CDCl3): d= 15.4 (C-8), 25.8
(C-7), 38.5 (C-9), 67.3 (C-10), 114.5–156.5 (C-11–C-16), 119.5
(C-18), 122.0–159.5 (C-2–C-6), 127.3–141.5 (C-20–C-25),
144.0 (C-17), 190.8 (C-19). Anal. calcd for C24H21NO2Cl2:
C67.61, H4.96, N3.29. Found C67.60, H4.90, N3.23.
2.2.4. 5-Ethyl-2-{[4-(1-(4-hydroxyphenyl)-2-propan-1-one-3-
yl)]phenoxyethyl} pyridine (4d)
m.p. 178–179 C. Yield 78%. Rf: 0.59. IR (KBr): t= 3057
(Ar-H), 2945, 2832 (–CH2–), 1660 (–C‚O), 1595 (–
CH‚CH–), 1216, 1033 (C–O–C), 3375 (–OH). 1H NMR
(CDCl3, 400 MHz): d= 1.15 (t, 3H, –CH3), 2.58 (q, 2H, –
CH2), 3.15 (t, 2H, –CH2), 4.36 (t, 2H, –CH2–O), 5.15 (s, 1H,
–OH), 7.01–8.05 (m, 8H, Ar-H), 7.12 (d, 1H, ‚CH–CO),
7.19 (d, 1H, –CH), 7.37–8.31 (m, 3H, Pyridine-H); 13C NMR
(100 MHz, CDCl3): d= 15.5 (C-8), 25.1 (C-7), 38.0 (C-9),
67.5 (C-10), 115.5-156.0 (C-11–C-16), 116.3–132.0 (C-20–C-
25), 119.2 (C-18), 122.4–160.5 (C-2–C-6), 144.5 (C-17), 190.5
(C-19). Anal. calcd for C24H23NO3: C77.19, H6.21, N3.75.
Found C77.13, H6.16, N3.70.
2.2.5. 5-Ethyl-2-{[4-(1-(2,6-chloro-5-ﬂuorophenyl)-2-propan-1-
one-3-yl)]phenoxy ethyl}pyridine (4e)
m.p. 101–103 C. Yield 85%. Rf: 0.53. IR (KBr): t= 3065
(Ar-H), 2955, 2837 (–CH2–), 1657 (–C‚O), 1589 (–
CH‚CH–), 1225, 1036 (C–O–C), 976 (C–F), 747 (C–Cl). 1H
NMR (CDCl3, 400 MHz): d= 1.16 (t, 3H, –CH3), 2.55 (q,
2H, –CH2), 3.17 (t, 2H, –CH2), 4.33 (t, 2H, –CH2–O), 7.03–
7.32 (m, 6H, Ar-H), 7.11 (d, 1H, ‚CH–CO), 7.19 (d, 1H, –
CH), 7.37–8.29 (m, 3H, Pyridine-H); 13C NMR (100 MHz,
CDCl3): d= 15.2 (C-8), 25.4 (C-7), 38.0 (C-9), 67.3 (C-10),
115.5–156.5 (C-11–C-16), 117.5–162.0 (C-20–C-25), 119.5 (C-
18), 122.0–160.0 (C-2–C-6), 144.2 (C-17), 190.3 (C-19). Anal.




m.p. 115–120 C. Yield 80%. Rf: 0.55. IR (KBr): t= 3060
(Ar-H), 2950, 2835 (–CH2–), 1662 (–C‚O), 1599 (–
CH‚CH–), 1223, 1033 (C–O–C). 1H NMR (CDCl3,
Characterization and pharmacological evaluation of new pyridine analogs 83400 MHz): d= 1.16 (t, 3H, –CH3), 2.34 (s, 3H, –CH3), 2.55 (q,
2H, –CH2), 3.18 (t, 2H, –CH2), 4.32 (t, 2H, –CH2–O), 6.84–
7.84 (m, 8H, Ar-H), 7.11 (d, 1H, ‚CH–CO), 7.19 (d, 1H, –
CH), 7.39–8.30 (m, 3H, Pyridine-H); 13C NMR (100 MHz,
CDCl3): d= 15.4 (C-8), 21.7 (C-26), 25.8 (C-7), 37.4 (C-9),
67.4 (C-10), 115.0–155.3 (C-11–C-16), 119.7 (C-18), 123.4–
160.9 (C-2–C-6), 127.5–142.4 (C-20–C-25), 144.2 (C-17),
190.0 (C-19). Anal. calcd for C25H25NO2: C80.83, H6.78,
N3.77. Found C80.81, H6.74, N3.71.
2.2.7. 5-Ethyl-2-{[4-(1-(1-phenyl)-2-propan-1-one-3-
yl)]phenoxyethyl}pyridine (4g)
m.p. 90–92 C. Yield 83%. Rf: 0.53. IR (KBr): t = 3055 (Ar-
H), 2947, 2832 (–CH2–), 1657 (–C‚O), 1596 (–CH‚CH–),
1217, 1029 (C–O–C). 1H NMR (CDCl3, 400 MHz): d= 1.18
(t, 3H, –CH3), 2.56 (q, 2H, –CH2), 3.17 (t, 2H, –CH2), 4.30
(t, 2H, –CH2–O), 7.01–7.81 (m, 9H, Ar-H), 7.13 (d, 1H,
‚CH–CO), 7.18 (d, 1H, –CH), 7.38–8.32 (m, 3H, Pyridine-
H); 13C NMR (100 MHz, CDCl3): d= 15.5 (C-8), 25.5 (C-
7), 38.2 (C-9), 67.3 (C-10), 115.5–156.2 (C-11–C-16), 119.5
(C-18), 122.4–160.5 (C-2–C-6), 127.8–138.0 (C-20–C-25),
144.5 (C-17), 190.2 (C-19). Anal. calcd for C24H23NO2:
C80.64, H6.49, N3.93. Found C80.63, H6.45, N3.86.
2.2.8. 5-Ethyl-2-{[4-(1-(4-ﬂuorophenyl)-2-propan-1-one-3-
yl)]phenoxyethyl }pyridine (4h)
m.p. 100–103 C. Yield 79%. Rf: 0.54. IR (KBr): t= 3062 (Ar-
H), 2953, 2838 (–CH2–), 1661 (–C‚O), 1594 (–CH‚CH–),
1222, 1037 (C–O–C), 970 (C–F). 1H NMR (CDCl3,
400 MHz): d= 1.18 (t, 3H, –CH3), 2.56 (q, 2H, –CH2), 3.16
(t, 2H, –CH2), 4.33 (t, 2H, –CH2–O), 7.05–7.79 (m, 8H, Ar-
H), 7.14 (d, 1H, ‚CH–CO), 7.19 (d, 1H, –CH), 7.39-8.29 (m,
3H, Pyridine-H); 13C NMR (100 MHz, CDCl3): d= 15.4 (C-
8), 25.3 (C-7), 38.0 (C-9), 67.0 (C-10), 115.5–156.5 (C-11–C-
16), 116.5–168.0 (C-20–C-25), 119.5 (C-18), 122.5–160.3 (C-2–
C-6), 144.2 (C-17), 190.3 (C-19). Anal. calcd for C24H22NO2F:
C76.78, H5.91, N3.73. Found C76.74, H5.86, N3.66.
2.2.9. 5-Ethyl-2-{[4-(1-(2,4-ﬂuorophenyl)-2-propan-1-one-3-
yl)]phenoxyethyl }pyridine (4i)
m.p. 75–78 C.Yield 81%.Rf: 0.57. IR (KBr): t= 3064 (Ar-H),
2949, 2834 (–CH2–), 1658 (–C‚O), 1598 (–CH‚CH–), 1217,
1030 (C–O–C), 973 (C–F). 1H NMR (CDCl3, 400 MHz):
d= 1.16 (t, 3H, –CH3), 2.54 (q, 2H, –CH2), 3.15 (t, 2H, –
CH2), 4.30 (t, 2H, –CH2–O), 6.87–7.77 (m, 7H, Ar-H), 7.12 (d,
1H, ‚CH–CO), 7.17 (d, 1H, –CH), 7.38–8.32 (m, 3H, Pyri-
dine-H); 13C NMR (100 MHz, CDCl3): d= 15.3 (C-8), 25.6
(C-7), 38.4 (C-9), 67.5 (C-10), 105.5–169.5 (C-20–C-25),
115.1–156.2 (C-11–C-16), 119.2 (C-18), 122.4–160.5 (C-2–C-
6), 144.0 (C-17), 190.1 (C-19). Anal. calcd for C24H21NO2F2:
C73.27, H5.38, N3.56. Found C73.25, H5.34, N3.49.
2.2.10. 5-Ethyl-2-{[4-(1-(4-bromophenyl)-2-propan-1-one-3-
yl)]phenoxyethyl}-pyridine (4j)
m.p. 102–104 C. Yield 85%. Rf: 0.56. IR (KBr): t= 3064 (Ar-
H), 2953, 2830 (–CH2–), 1660 (–C‚O), 1595 (–CH‚CH–),
1225, 1032 (C–O–C), 858 (C-Br). 1H NMR (CDCl3,
400 MHz): d= 1.15 (t, 3H, –CH3), 2.55 (q, 2H, –CH2), 3.18
(t, 2H, –CH2), 4.34 (t, 2H, –CH2–O), 7.00–8.01 (m, 8H, Ar-
H), 7.13 (d, 1H,‚CH–CO), 7.16 (d, 1H, –CH), 7.37–8.30 (m,
3H, Pyridine-H); 13C NMR (100 MHz, CDCl3): d= 15.0 (C-8), 24.5 (C-7), 38.2 (C-9), 67.1 (C-10), 115.5–156.0 (C-11–C-
16), 118.5 (C-18), 121.4–159.5 (C-2–C-6), 132.1–136.9 (C-20–
C-25), 144.2 (C-17), 189.5 (C-19).Anal. calcd forC24H22NO2Br:
C66.06, H5.08, N3.21. Found C66.03, H5.02, N3.15.
2.2.11. 5-Ethyl-2-{[4-(1-(3,4-dichlorophenyl)-2-propan-1-one-
3-yl)]phenoxyethyl} pyridine (4k)
m.p. 105–110 C. Yield 84%. Rf: 0.55. IR (KBr): t= 3067 (Ar-
H), 2947, 2829 (–CH2–), 1664 (–C‚O), 1593 (–CH‚CH–),
1220, 1031 (C–O–C), 744 (C–Cl). 1H NMR (CDCl3,
400 MHz): d= 1.16 (t, 3H, –CH3), 2.55 (q, 2H, –CH2), 3.19 (t,
2H, –CH2), 4.32 (t, 2H, –CH2–O), 7.01–7.76 (m, 7H, Ar-H),
7.11 (d, 1H,‚CH–CO), 7.18 (d, 1H, –CH), 7.38–8.32 (m, 3H,
Pyridine-H); 13C NMR (100 MHz, CDCl3): d= 15.5 (C-8),
25.1 (C-7), 37.2 (C-9), 66.5 (C-10), 114.5–155.2 (C-11–C-16),
119.8 (C-18), 122.4–160.5 (C-2–C-6), 130.4–139.5 (C-20–C-25),
143.5 (C-17), 188.9 (C-19). Anal. calcd for C24H21NO2Cl2:
C67.61, H4.96, N3.29. Found C67.58, H4.90, N3.23.
2.2.12. 5-Ethyl-2-{[4-(1-(4-chlorophenyl)-2-propan-1-one-3-
yl)]phenoxyethyl} pyridine (4l)
m.p. 138–140 C. Yield 88%. Rf: 0.53. IR (KBr): t= 3028 (Ar-
H), 2944, 2827 (–CH2–), 1659 (–C‚O), 1596 (–CH‚CH–),
1224, 1037 (C–O–C), 746 (C–Cl). 1H NMR (CDCl3,
400 MHz): d= 1.15 (t, 3H, –CH3), 2.57 (q, 2H, –CH2), 3.18
(t, 2H, –CH2), 4.30 (t, 2H, –CH2–O), 7.03–7.86 (m, 8H, Ar-
H), 7.10 (d, 1H,‚CH–CO), 7.19 (d, 1H, –CH), 7.37–8.32 (m,
3H, Pyridine-H); 13C NMR (100 MHz, CDCl3): d= 15.4 (C-
8), 24.8 (C-7), 38.3 (C-9), 67.3 (C-10), 114.5–156.0 (C-11–C-
6), 118.2 (C-18), 121.5–160.8 (C-2–C-6), 129.5–140.5 (C-20–C-
25), 144.5 (C-17), 190.5 (C-19). Anal. calcd for C24H22NO2Cl:
C73.56, H5.66, N3.57. Found C73.52, H5.61, N3.55.
2.2.13. 5-Ethyl-2-{[4-(1-(3-methoxyphenyl)-2-propan-1-one-3-
yl)]phenoxyethyl} pyridine (4m)
m.p. 75–80 C. Yield 70%. Rf: 0.52. IR (KBr): t= 3066 (Ar-H),
2952, 2833 (–CH2–), 1664 (–C‚O), 1594 (–CH‚CH–), 1220,
1032 (C–O–C). 1H NMR (CDCl3, 400 MHz): d= 1.14 (t, 3H,
–CH3), 2.58 (q, 2H, –CH2), 3.16 (t, 2H, –CH2), 3.85 (s, 3H, –
OCH3) 4.34 (t, 2H, –CH2–O), 6.96–8.11 (m, 8H, Ar-H), 7.11
(d, 1H,‚CH–CO), 7.16 (d, 1H, –CH), 7.39-8.30 (m, 3H, Pyri-
dine-H); 13C NMR (100 MHz, CDCl3): d= 15.5 (C-8), 25.5
(C-7), 38.5 (C-9), 55.5 (C-26), 68.5 (C-10), 115.3–156.5 (C-11–
C-16), 117.3–161.5 (C-20–C-25), 119.2 (C-18), 122.6–161.5 (C-
2–C-6), 144.1 (C-17), 190.1 (C-19). Anal. calcd for C25H25NO3:
C77.49, H6.50, N3.61. Found C77.45, H6.48, N3.52.
2.2.14. 5-Ethyl-2-{[4-(1-(3-ﬂuorophenyl)-2-propan-1-one-3-
yl)]phenoxyethyl} pyridine (4n)
m.p. 87–90 C. Yield 80%. Rf: 0.54. IR (KBr): t= 3062 (Ar-
H), 2956, 2835 (–CH2–), 1660 (–C‚O), 1597 (–CH‚CH–),
1219, 1032 (C–O–C), 976 (C–F). 1H NMR (CDCl3,
400 MHz): d= 1.11 (t, 3H, –CH3), 2.53(q, 2H, –CH2), 3.14
(t, 2H, –CH2), 4.31 (t, 2H, –CH2–O), 7.00–7.58 (m, 8H, Ar-
H), 7.13 (d, 1H, ‚CH–CO), 7.18 (d, 1H, –CH), 7.39-8.30
(m, 3H, Pyridine-H); 13C NMR (100 MHz, CDCl3): d= 15.8
(C-8), 25.3 (C-7), 38.0 (C-9), 55.8 (C-26), 67.5 (C-10), 114.5–
164.0 (C-20–C-25), 115.5–156.1 (C-11–C-16), 119.2 (C-18),
122.5–160.5 (C-2–C-6), 144.8 (C-17), 189.5 (C-19), Anal. calcd
for C24H22NO2F: C76.78, H5.91, N3.73. Found C76.72,
H5.86, N3.70.
84 N.B. Patel, H.R. Patel2.2.15. 5-Ethyl-2-{[4-(1-(3,4-diﬂuorophenyl)-2-propan-1-one-
3-yl)]phenoxyethyl} pyridine (4o)
m.p. limpid. Yield 82%. Rf: 0.55. IR (KBr): t= 3060 (Ar-H),
2950, 2835 (–CH2–), 1662 (–C‚O), 1599 (–CH‚CH), 1223,
1033 (C–O–C), 978 (C–F). 1H NMR (CDCl3, 400 MHz):
d= 1.12 (t, 3H, –CH3), 2.54 (q, 2H, –CH2), 3.16 (t, 2H, –
CH2), 4.32 (t, 2H, –CH2–O), 7.02–7.56 (m, 7H, Ar-H), 7.14
(d, 1H,‚CH–CO), 7.19 (d, 1H, –CH), 7.37–8.28 (m, 3H, Pyr-
idine-H); 13C NMR (100 MHz, CDCl3): d= 15.5 (C-8), 25.1
(C-7), 38.2 (C-9), 67.1 (C-10), 115.5–156.0 (C-11–C-16),
116.3–155.5 (C-20–C-25), 119.6 (C-18), 122.4–160.2 (C-2–C-
6), 144.5 (C-17), 190.5 (C-19). Anal. calcd for C24H21NO2F2:
C73.27, H5.38, N3.56. Found C73.21, H5.33, N3.48.
2.3. General preparation of the compounds 5a–o
A mixture of freshly prepared solution of sodium ethoxide
(0.02 mol Na in 50 mL ethanol), 4a–o (0.01 mol) and guani-
dine nitrate (0.01 mol) was reﬂuxed for 8–12 h; reaction pro-
gress was monitored by TLC (tolune:ethyl acetate, 7.5:2.5).
After completion of reaction, the mixture was concentrated
under vacuum and the remaining reaction mass was poured
into crushed ice; the solid was separated out and stirred for
1 h to maintain neutral pH with dilute glacial acetic acid.
The mass was ﬁltered and washed with water, dried and recrys-
tallized from ethanol (Fig. 2).
2.3.1. 5-Ethyl-2-{[4-(6-(2,4-dichloro-5-ﬂuorophenyl)-2-
aminopyrimidin-4-yl)] phenoxyethyl} pyridine (5a)
m.p. 95–98 C. Yield 74%. Rf: 0.42. IR (KBr): t= 3355, 3222
(–NH2), 3062 (Ar-H), 2954, 2837 (–CH2–), 1602 (–C‚N),
1225, 1036 (C–O–C), 973 (C-F), 745 (C–Cl). 1H NMR (CDCl3,
400 MHz): d= 1.13 (t, 3H, –CH3), 2.54 (q, 2H, –CH2), 3.17 (t,
2H, –CH2), 4.33 (t, 2H, –CH2–O), 5.18 (s, 2H, –NH2), 6.90–
7.82 (m, 8H, Ar-H), 7.39–8.32 (m, 3H, Pyridine-H), 7.84 (s,
1H, Pyrimidine-H); 13C NMR (100 MHz, CDCl3): d= 15.3
(C-8), 25.2 (C-7), 38.0 (C-9), 67.0 (C-10), 103.5 (C-22),
114.0–154.4 (C-11–C-16), 118.7–161.4 (C-24–C-29), 123.5–
160.5 (C-2–C-6), 160.7 (C-21), 163.2 (C-17), 165.0 (C-19) Anal.




m.p. 100–102 C. Yield 52%. Rf: 0.40. IR (KBr): t= 3352,
3224 (–NH2), 3065 (Ar-H), 2957, 2834 (–CH2–), 1609 (–
C‚N), 1223, 1033 (C–O–C). 1H NMR (CDCl3, 400 MHz):


































Figure 2 Pyrimidines 5a–o.CH2), 3.83 (s, 3H, –OCH3) 4.34 (t, 2H, –CH2–O), 5.12 (s,
2H, –NH2), 6.89–7.84 (m, 8H, Ar-H), 7.40–8.32 (m, 3H, Pyri-
dine-H), 7.86 (s, 1H, Pyrimidine-H); 13C NMR (100 MHz,
CDCl3): d= 15.4 (C-8), 25.0 (C-7), 37.5 (C-9), 55.8 (C-30),
67.3 (C-10), 103.4 (C-22), 114.5–160.5 (C-24–C-29), 115.3–
155.5 (C-11–C-16), 123.8–161.0 (C-2–C-6), 160.5 (C-21),
164.5 (C-17), 165.1 (C-19), Anal. calcd for C26H26N4O2:
C73.22, H6.14, N13.14. Found C73.14, H6.08, N13.07.
2.3.3. 5-Ethyl-2-{[4-(6-(2,4-dichlorophenyl)-2-aminopyrimidin-
4-yl)]phenoxyethyl} pyridine (5c)
m.p. 115–118 C. Yield 78%. Rf: 0.43. IR (KBr): t= 3358, 3227
(–NH2), 3057 (Ar-H), 2953, 2836 (–CH2–), 1607 (–C‚N), 1227,
1037 (C–O–C), 746 (C–Cl). 1H NMR (CDCl3, 400 MHz):
d= 1.15 (t, 3H, –CH3), 2.52 (q, 2H, –CH2), 3.16 (t, 2H, –CH2),
4.32 (t, 2H, –CH2–O), 5.22 (s, 2H, NH2), 6.88–7.81 (m, 8H,
Ar-H), 7.39–8.32 (m, 3H, Pyridine-H), 7.86 (s, 1H, Pyrimidine-
H); 13C NMR (100 MHz, CDCl3): d= 15.2 (C-8), 26.1 (C-7),
37.3 (C-9), 67.5 (C-10), 104.2 (C-22), 115.1–155.2 (C-11–C-16),
123.6–161.9 (C-2–C-6), 127.4–135.5 (C-24–C-29), 160.5 (C-21),
163.6 (C-17), 165.1 (C-19). Anal. calcd for C25H22N4OCl2:
C64.52, H4.76, N12.04. Found C64.46, H4.69, N12.00.
2.3.4. 5-Ethyl-2-{[4-(6-(4-hydroxyphenyl)-2-aminopyrimidin-
4-yl)]phenoxyethyl} pyridine (5d)
m.p. >300 C. Yield 50%. Rf: 0.44. IR (KBr): t= 3355, 3224
(–NH2), 3064 (Ar-H), 2955, 2832 (–CH2–), 1600 (–C‚N),
1220, 1032 (C–O–C), 3357 (–OH). 1H NMR (CDCl3,
400 MHz): d= 1.13 (t, 3H, –CH3), 2.54 (q, 2H, –CH2), 3.15
(t, 2H, –CH2), 4.33 (t, 2H, –CH2–O), 9.85 (s, 1H, –OH), 5.12
(s, 2H, –NH2), 6.84–7.78 (m, 8H, Ar-H), 7.39–8.30 (m, 3H,
Pyridine-H), 7.85 (s, 1H, Pyrimidine-H); 13C NMR
(100 MHz, CDCl3): d= 15.7 (C-8), 25.5 (C-7), 37.6 (C-9),
67.3 (C-10), 103.5 (C-22), 115.7–155.7 (C-11–C-16), 116.3–
158.5 (C-24–C-29), 122.9–159.9 (C-2–C-6), 160.3 (C-21),
163.8 (C-17), 165.2 (C-19), Anal. calcd for C25H24N4O2:
C72.80, H5.86, N13.58. Found C72.74, H5.78, N13.52.
2.3.5. 5-Ethyl-2-{[4-(6-(2,6-chloro-5-ﬂuorophenyl)-2-
aminopyrimidin-4-yl)] phenoxyethyl}pyridine (5e)
m.p. 105–108 C. Yield 76%. Rf: 0.40. IR (KBr): t= 3348,
3219 (–NH2), 3062 (Ar-H), 2953, 2830 (–CH2–), 1606 (–
C‚N), 1220, 1034 (C–O–C), 975 (C–F), 747 (C–Cl). 1H
NMR (CDCl3, 400 MHz): d= 1.12 (t, 3H, –CH3), 2.55 (q,
2H, –CH2), 3.16 (t, 2H, –CH2), 4.31 (t, 2H, –CH2–O), 5.24
(s, 2H, –NH2), 6.91–7.83 (m, 8H, Ar-H), 7.38–8.30 (m, 3H,
Pyridine-H), 7.85 (s, 1H, Pyrimidine-H); 13C NMR
(100 MHz, CDCl3): d= 15.2 (C-8), 25.1 (C-7), 38.2 (C-9),
67.2 (C-10), 103.2 (C-22), 113.9–154.1 (C-11–C-16), 118.3–
161.4 (C-24–C-29), 123.0–160.4 (C-2–C-6), 160.5 (C-21),
163.0 (C-17), 165.4 (C-19), Anal. calcd for C25H21N4OCl2F:
C62.12, H4.38, N11.59. Found C62.04, H4.31, N11.55.
2.3.6. 5-Ethyl-2-{[4-(6-(4-methylphenyl)-2-aminopyrimidin-4-
yl)]phenoxyethyl} pyridine (5f)
m.p. 133–136 C. Yield 78%. Rf: 0.42. IR (KBr): t= 3355,
3220 (–NH2), 3057 (Ar-H), 2952, 2834 (–CH2–), 1610 (–
C‚N), 1220, 1034 (C–O–C). 1H NMR (CDCl3, 400 MHz):
d= 1.15 (t, 3H, –CH3), 2.33 (s, 3H, –CH3), 2.53 (q, 2H, –
CH2), 3.17 (t, 2H, –CH2), 4.32 (t, 2H, –CH2–O), 5.15 (s, 2H,
–NH2), 6.89–7.80 (m, 8H, Ar-H), 7.39–8.30 (m, 3H, Pyri-
Characterization and pharmacological evaluation of new pyridine analogs 85dine-H), 7.85 (s, 1H, Pyrimidine-H); 13C NMR (100 MHz,
CDCl3): d= 15.4 (C8), 21.7 (C30), 25.5 (C7), 37.5 (C9), 67.5
(C10), 103.2 (C22), 115.0–155.4 (C11–C16), 123.4–160.9 (C2–
C6), 129.2–144.4 (C24–C29), 160.9 (C21), 163.5 (C17), 165.5
(C19), Anal. calcd for C26H26N4O: C76.07, H6.38, N13.65.
Found C76.00, H6.32, N13.57.
2.3.7. 5-Ethyl-2-{[4-(6-(1-phenyl)-2-aminopyrimidin-4-
yl)]phenoxyethyl}pyridine (5g)
m.p. 110–115 C.Yield 65%.Rf: 0.44. IR (KBr): t= 3356, 3225
(–NH2), 3058 (Ar-H), 2952, 2832 (–CH2–), 1605 (–C‚N), 1227,
1038 (C–O–C). 1HNMR (CDCl3, 400 MHz): d= 1.13 (t, 3H, –
CH3), 2.52 (q, 2H, –CH2), 3.18 (t, 2H, –CH2), 4.30 (t, 2H, –CH2–
O), 5.20 (s, 2H, –NH2), 6.89–7.82 (m, 8H, Ar-H), 7.38–8.31 (m,
3H, Pyridine-H), 7.87 (s, 1H, Pyrimidine-H); 13C NMR
(100 MHz, CDCl3): d= 15.3 (C8), 25.1 (C7), 38.2 (C9), 67.2
(C10), 103.7 (C22), 114.9–154.1 (C11–C16), 118.7–161.4 (C24–
C29), 123.6–160.4 (C2–C6), 160.5 (C21), 163.2 (C17), 164.9
(C19), Anal. calcd for C26H24N4O: C75.73, H6.10, N14.13.
Found C75.68, H6.04, N14.10.
2.3.8. 5-Ethyl-2-{[4-(6-(4-ﬂuorophenyl)-2-aminopyrimidin-4-
yl)]phenoxyethyl} pyridine (5h)
m.p. 244–246 C. Yield 70%. Rf: 0.45. IR (KBr): t= 3356,
3222 (–NH2), 3064 (Ar-H), 2950, 2835 (–CH2–), 1602 (–
C‚N), 1226, 1036 (C–O–C), 975 (C–F). 1H NMR (CDCl3,
400 MHz): d= 1.15 (t, 3H, –CH3), 2.53 (q, 2H, –CH2), 3.17
(t, 2H, –CH2), 4.31 (t, 2H, –CH2–O), 5.16 (s, 2H, –NH2),
6.88–7.80 (m, 8H, Ar-H), 7.39-8.32 (m, 3H, Pyridine-H), 7.84
(s, 1H, Pyrimidine-H); 13C NMR (100 MHz, CDCl3):
d= 14.9 (C8), 25.4 (C7), 38.3 (C9), 67.4 (C10), 103.9 (C22),
114.1–154.3 (C11–C16), 116.0–163.0 (C24–C29), 123.9–160.9
(C2–C6), 160.7 (C21), 163.0 (C17), 164.5 (C19), Anal. calcd




m.p. 135–139 C. Yield 72%. Rf: 0.41. IR (KBr): t= 3347, 3225
(–NH2), 3066 (Ar-H), 2945, 2832 (–CH2–), 1604 (–C‚N), 1220,
1034 (C–O–C), 978 (C–F). 1H NMR (CDCl3, 400 MHz):
d= 1.14 (t, 3H, –CH3), 2.54 (q, 2H, –CH2), 3.16 (t, 2H, –
CH2), 4.32 (t, 2H, –CH2–O), 5.18 (s, 2H, –NH2), 6.90–7.83 (m,
8H, Ar-H), 7.37–8.30 (m, 3H, Pyridine-H), 7.86 (s, 1H, Pyrimi-
dine-H); 13C NMR (100 MHz, CDCl3): d= 15.1 (C8), 25.4
(C7), 38.1 (C9), 67.8 (C10), 103.5 (C22), 114.2–153.9 (C11–
C16), 116.6–164.5 (C24–C29), 123.5–160.8 (C2–C6), 160.5
(C21), 163.2 (C17), 164.4 (C19), Anal. calcd for C25H22N4OF2:
C69.43, H5.13, N12.96. Found C69.37, H5.08, N12.92.
2.3.10. 5-Ethyl-2-{[4-(6-(4-bromophenyl)-2-aminopyrimidin-4-
yl)]phenoxyethyl} pyridine (5j)
m.p. 115–117 C yield. 77%. Rf: 0.40. IR (KBr): t= 3354,
3225 (–NH2), 3057 (Ar-H), 2952, 2837 (–CH2–), 1608 (–
C‚N), 1224, 1032 (C–O–C), 860 (C-Br). 1H NMR (CDCl3,
400 MHz): d= 1.15(t, 3H, –CH3), 2.53 (q, 2H, –CH2), 3.18
(t, 2H, –CH2), 4.33 (t, 2H, –CH2–O), 5.14 (s, 2H, –NH2),
6.86–7.81 (m, 8H, Ar-H), 7.38–8.33 (m, 3H, Pyridine-H),
7.85(s, 1H, Pyrimidine-H); 13C NMR (100 MHz, CDCl3):
d= 15.2 (C8), 25.1 (C7), 38.8 (C9), 67.7 (C10), 103.9 (C22),
114.1–154.2 (C11–C16), 123.1–132.1 (C24–C29), 123.8–160.6(C2–C6), 160.7 (C21), 163.1 (C17), 164.5 (C19), Anal. calcd




m.p. 125–130 C. Yield 73%. Rf: 0.43. IR (KBr): t= 3356,
3227 (–NH2), 3066 (Ar-H), 2955, 2838 (–CH2–), 1605 (–
C‚N), 1225, 1037 (C–O–C), 748 (C–Cl). 1H NMR (CDCl3,
400 MHz): d= 1.13 (t, 3H, –CH3), 2.55 (q, 2H, –CH2), 3.15
(t, 2H, –CH2), 4.35 (t, 2H, –CH2–O), 5.17 (s, 2H, –NH2),
6.92-7.83 (m, 8H, Ar-H), 7.41–8.30 (m, 3H, Pyridine-H), 7.84
(s, 1H, Pyrimidine-H); 13C NMR (100 MHz, CDCl3):
d= 15.8 (C8), 25.4 (C7), 38.3 (C9), 67.5 (C10), 103.8 (C22),
114.1–154.3 (C11–C16), 123.6–160.8 (C2–C6), 127.0–133.5
(C24–C29), 160.5 (C21), 160.5 (C21), 163.1 (C17), 164.5
(C19), Anal. calcd for C25H22N4OCl2: C64.52, H4.76,
N12.04. Found C64.48, H4.71, N12.00.
2.3.12. 5-Ethyl-2-{[4-(6-(4-chlorophenyl)-2-aminopyrimidin-4-
yl)]phenoxyethyl} pyridine (5l)
m.p. 92–95 C. Yield 74%. Rf: 0.42. IR (KBr): t= 3356, 3227 (–
NH2), 3066 (Ar-H), 2955, 2838 (–CH2–), 1611 (–C‚N), 1225,
1037 (C–O–C), 748 (C–Cl). 1H NMR (CDCl3,
400 MHz):d= 1.17 (t, 3H, –CH3), 2.53 (q, 2H, –CH2), 3.14 (t,
2H, –CH2), 4.33 (t, 2H, –CH2–O), 5.10 (s, 2H, –NH2), 6.91–
7.82 (m, 8H, Ar-H), 7.40–8.31 (m, 3H, Pyridine-H), 7.83 (s, 1H,
Pyrimidine-H); 13C NMR (100 MHz, CDCl3): d= 15.7 (C8),
25.7 (C7), 38.5 (C9), 67.4 (C10), 103.7 (C22), 114.2–154.1 (C11–
C16), 123.9–161.0 (C2–C6), 128.9–134.5 (C24–C29), 160.5
(C21), 163.4 (C17), 164.1 (C19), Anal. calcd for C25H23N4OCl:
C69.68, H5.38, N13.00. Found C69.63, H5.34, N12.98.
2.3.13. 5-Ethyl-2-{[4-(6-(3-methoxyphenyl)-2-aminopyrimidin-
4-yl)]phenoxyethyl} pyridine (5m)
m.p. 98–111 C. Yield 54% Rf: 0.44. IR (KBr): t= 3356, 3225
(–NH2), 3066 (Ar-H), 2956, 2838 (–CH2–), 1609 (–C‚N),
1220, 1033 (C–O–C). 1H NMR (CDCl3, 400 MHz): d= 1.15
(t, 3H, –CH3), 2.53 (q, 2H, –CH2) 3.17 (t, 2H, –CH2), 3.82
(s, 3H, –OCH3), 5.22 (s, 2H, –NH2), 4.34 (t, 2H, –CH2–O),
6.90–7.85 (m, 8H, Ar-H), 7.40–8.33 (m, 3H, Pyridine-H),
7.85 (s, 1H, Pyrimidine-H); 13C NMR (100 MHz, CDCl3):
d= 15.2 (C8), 25.6 (C7), 38.5 (C9), 55.7 (C30), 67.8 (C10),
103.2 (C22), 113.9–154.5 (C11–C16), 114.9–160.0 (C24–C29),
123.1–160.5 (C2–C6), 160.1 (C21), 163.2 (C17), 164.3 (C19).




m.p. 95–100 C. Yield 72%. Rf: 0.43. IR (KBr): t= 3352, 3225
(–NH2), 3065 (Ar-H), 2957, 2838 (–CH2–), 1601 (–C‚N), 1218,
1029 (C–O–C), 976 (C–F). 1H NMR (CDCl3, 400 MHz):
d= 1.14 (t, 3H, –CH3), 2.52 (q, 2H, –CH2), 3.18 (t, 2H, –
CH2), 4.33 (t, 2H, –CH2–O), 5.14 (s, 2H, –NH2), 6.88–7.84 (m,
8H, Ar-H), 7.40–8.32 (m, 3H, Pyridine-H), 7.84 (s, 1H, Pyrimi-
dine-H); 13C NMR (100 MHz, CDCl3): d= 25.4 (C7), 38.3
(C9), 67.4 (C10), 103.5 (C22), 114.1–154.3 (C11–C16), 115.5–
163.5 (C24–C29), 123.8–161.8 (C2–C6), 160.7 (C21), 163.0
(C17), 164.3 (C19), Anal. calcd for C25H23N4OF: C72.45,
H5.59, N13.52. Found C72.40, H5.54, N13.49.
86 N.B. Patel, H.R. Patel2.3.15. 5-Ethyl-2-{[4-(6-(3,4-diﬂuorophenyl)-2-
aminopyrimidine-4-yl)]phenoxyethyl} pyridine (5o)
m.p. 115–118 C.Yield 74%.Rf: 0.44. IR (KBr): t= 3357, 3218
(–NH2), 3062 (Ar-H), 2957, 2832 (–CH2–), 1602 (–C‚N), 1225,
1034 (C–O–C), 975 (C–F). 1H NMR (CDCl3, 400 MHz):
d= 1.13 (t, 3H, –CH3), 2.53 (q, 2H, –CH2), 3.17(t, 2H, –
CH2), 4.34 (t, 2H, –CH2–O), 5.20 (s, 2H, –NH2), 6.89–7.85 (m,
8H, Ar-H), 7.39–8.33 (m, 3H, Pyridine-H), 7.86 (s, 1H, Pyrimi-
dine-H); 13C NMR (100 MHz, CDCl3): d= 14.6 (C8), 25.9
(C7), 37.9 (C9), 68.0 (C10), 102.9 (C22), 114.0–154.1 (C11–
C16), 115.0–149.5 (C24–C29), 123.6–160.9 (C2–C6), 160.6
(C21), 162.9 (C17), 163.5 (C19). Anal. calcd for C25H22N4OF2:
C69.43, H5.13, N12.96. Found C69.38, H5.06, N12.92.
2.4. General preparation of the compounds 6a–o
A solution of the 5a–o (0.01 mol) and the appropriate benzoyl
chloride (0.02 mol) in pyridine (10 mL) was heated under re-
ﬂux for 6–8 h and continued till the reaction completed. The
progress of reaction was monitored by TLC (tolune:ethyl ace-
tate, 7.5:2.5). After completion of the reaction, the mass was
dumped into ice cold water; the solid obtained was ﬁltered,
washed with cold water until neutral pH and dried and recrys-
tallized from ethanol Fig. 3.
2.4.1. 5-Ethyl-2-{[4-(6-(2,4-dichloro-5-ﬂuorophenyl)-2-(3,4-
dichlorobenzamidopyrimidin-4-yl)]pheno-xyethyl} pyridine (6a)
m.p. 135–137 C. Yield 67%. Rf: 0.61. IR (KBr): t= 3064
(Ar-H), 2957, 2832 (–CH2–), 1610 (–C‚N), 1225, 1033 (C–
O–C), 1674 (Amide-1), 1533 (Amide-2), 1246 (Amide-3), 975
(C–F), 747 (C–Cl). 1H NMR (CDCl3, 400 MHz): d= 1.14
(t, 3H, –CH3), 2.32 (s, 3H, –CH3), 2.54 (q, 2H, –CH2), 3.15
(t, 2H, –CH2), 4.35 (t, 2H, –CH2–O), 7.05–8.14 (m, 11H, Ar-
H), 7.32–8.32 (m, 3H, Pyridine-H), 7.86 (s, 1H, Pyrimidine-
H), 9.32 (s, 1H –NHCO); 13C NMR (100 MHz, CDCl3):
d= 15.7 (C8), 21.5 (C37), 25.8 (C7), 37.6 (C9), 67.3 (C10),
103.7 (C22), 115.3–155.6 (C11–C16), 123.3–160.6 (C2–C6),
127.2–144.6 (C24–C35), 161.4 (C21), 161.0 (C19), 163.2
(C17), 165.1 (C36), Anal. calcd for C32H23N4O2Cl4F:
C58.56, H3.53, N8.54. Found C58.56, H3.53, N8.54.
2.4.2. 5-Ethyl-2-{[4-(6-(4-methoxyphenyl)-2-(3,4-
dichlorobenzamidopyrimidin-4-yl)] phenoxyethyl}pyridine (6b)
m.p. 70–72 C. Yield 63%. Rf: 0.63. IR (KBr): t= 3063 (Ar-H),
2956, 2838 (–CH2–), 1612 (–C‚N), 1675 (Amide-1), 1534
(Amide-2), 1245 (Amide-3) 1226, 1038 (C–O–C). 1H NMR













































Figure 3 Benzamido pyrimidines 6a–o.2.50 (q, 2H, –CH2), 3.18 (t, 2H, –CH2), 4.33 (t, 2H, –CH2–O),
7.03–8.14 (m, 11H, Ar-H), 7.33–8.31 (m, 3H, Pyridine-H), 7.82
(s, 1H, Pyrimidine-H), 9.31 (s, 1H –NHCO); 13C NMR
(100 MHz, CDCl3): d= 15.4 (C8), 21.8 (C37), 25.5 (C7), 37.4
(C9), 67.4 (C10), 103.7 (C22), 115.3–155.2 (C11–C16), 123.8–
161.0 (C2–C6), 127.0–144.6 (C24–C35), 161.3 (C21), 161.7
(C19), 163.4 (C17), 165.5 (C36), Anal. calcd for C33H28N4O3Cl2:
C66.11, H4.71, N9.35. Found C66.09, H4.73, N9.35.
2.4.3. 5-Ethyl-2-{[4-(6-(2,4-dichlorophenyl)-2-(3,4-
dichlorobenzamidopyrimidin-4-yl)] phenoxyethyl} pyridine (6c)
m.p. 112–115 C. Yield 65%. Rf: 0.64. IR (KBr): t= 3061
(Ar-H), 2954, 2833 (–CH2–), 1677 (Amide-1), 1604 (–C‚N),
1535 (Amide-2), 1246 (Amide-3), 1224, 1036 (C–O–C), 746
(C–Cl). 1H NMR (CDCl3, 400 MHz): d= 1.17 (t, 3H, –
CH3), 2.34 (s, 3H, –CH3), 2.55 (q, 2H, –CH2), 3.16 (t, 2H, –
CH2), 4.32 (t, 2H, –CH2–O), 7.00–8.10 (m, 11H, Ar-H),
7.33–8.33 (m, 3H, Pyridine-H), 7.82 (s, 1H, Pyrimidine-H),
9.30 (s, 1H –NHCO); 13C NMR (100 MHz, CDCl3):
d= 15.4 (C8), 21.5 (C37), 25.4 (C7), 37.6 (C9), 67.8 (C10),
103.3 (C22), 115.2–155.0 (C11–C16), 123.0–160.4 (C2–C6),
127.4–144.0 (C24–C35), 161.2 (C21), 161.4 (C19), 163.3
(C17), 165.6 (C36). Anal. calcd for C32H24 N4O2Cl4: C60.21,
H3.79, N8.78. Found C60.22, H3.73, N8.78.
2.4.4. 5-Ethyl-2-{[4-(6-(4-hydroxyphenyl)-2-(3,4-dichloro-
benzamidopyrimidin-4-yl)]phenoxy ethyl} pyridine (6d)
m.p. 116–118 C. Yield, 61%. Rf: 0.59. IR (KBr): t= 3367 (–
OH), 3057 (Ar-H), 2953, 2835 (–CH2–), 1671 (amide-1), 1604 (–
C‚N), 1534 (amide-2), 1245 (amide-3), 1223, 1034 (C–O–C).
1H NMR (CDCl3, 400 MHz): d= 1.15 (t, 3H, –CH3), 2.33 (s,
3H, –CH3), 2.54 (q, 2H, –CH2), 3.17(t, 2H, –CH2), 4.34 (t, 2H, –
CH2–O), 7.08–8.20 (m, 11H, Ar-H), 7.33–8.32(m, 3H, Pyridine-
H), 7.83 (s, 1H, Pyrimidine-H), 9.33 (s, 1H –NHCO); 13C NMR
(100 MHz, CDCl3): d= 15.5 (C8), 21.7 (C37), 25.6 (C7), 37.5
(C9), 67.5 (C10), 103.4 (C22), 115.2–155.6 (C11–C16), 123.5–
160.9 (C2–C6), 127.5–144.1 (C24–C35), 161.4 (C21), 161.6
(C19), 163.1 (C17), 165.7 (C36). Anal. calcd for C32H26N4O3Cl2:
C65.65, H4.48, N9.57. Found C65.62, H4.43, N9.55.
2.4.5. 5-Ethyl-2-{[4-(6-(2,6-chloro-5-ﬂuorophenyl)-2-(3,4-
dichlorobenzamidopyrimidin-4-yl)]pheno-xyethyl} pyridine (6e)
m.p. 122–124. Yield, 69%. Rf: 0.64. IR (KBr): t= 3063 (Ar-H),
2955, 2836 (–CH2–), 1676 (Amide-1), 1610 (–C‚N), 1533
(Amide-2), 1245 (Amide-3), 1217, 1036 (C–O–C). 1H NMR
(CDCl3, 400 MHz): d= 1.14 (t, 3H, –CH3), 2.28 (s, 3H, –CH3),
2.57 (q, 2H, –CH2), 3.20 (t, 2H, –CH2), 4.35 (t, 2H, –CH2–O),
7.09–8.09 (m, 11H, Ar-H), 7.34–8.32 (m, 3H, Pyridine-H), 7.80
(s, 1H, Pyrimidine-H), 9.33 (s, 1H –NHCO); 13C NMR
(100 MHz, CDCl3): d= 15.6 (C8), 21.6 (C37), 25.8 (C7), 37.7
(C9), 67.9 (C10), 103.7 (C22), 115.2–155.1 (C11–C16), 123.7–
160.8 (C2–C6), 127.6–144.6 (C24–C35), 161.0 (C21), 161.5
(C19), 163.4 (C17), 165.4 (C36). Anal. calcd for C32H23N4O2Cl4F:
C58.56, H3.53, N8.54. Found C58.53, H3.50, N8.55.
2.4.6. 5-Ethyl-2-{[4-(6-(4-methylphenyl)-2-(3,4-
dichlorobenzamidopyrimidin-4-yl)]phenoxy ethyl} pyridine (6f)
m.p. 132–134 C. Yield 71%. Rf: 0.67. IR (KBr): t= 3063 (Ar-
H), 2954, 2832 (–CH2–), 1672 (Amide-1), 1614 (–C‚N), 1537
(Amide-2), 1250 (Amide-3), 1222, 1031 (C–O–C). 1H NMR
(CDCl3, 400 MHz): d= 1.16 (t, 3H, –CH3), 2.30 (s, 3H, –
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O), 7.05–8.16 (m, 11H, Ar-H), 7.34–8.30 (m, 3H, Pyridine-H),
7.84 (s, 1H, Pyrimidine-H), 9.30 (s, 1H –NHCO); 13C NMR
(100 MHz, CDCl3): d= 15.5 (C8), 21.7 (C37), 25.6 (C7), 37.5
(C9), 67.6 (C10), 103.5 (C22), 115.0–155.4 (C11–C16), 123.3–
160.8 (C2–C6), 127.5–144.4 (C24–C35), 161.0 (C21), 161.5
(C19), 163.5 (C17), 165.3 (C36), Anal. calcd for C33H28N4O2Cl2:
C67.93, H4.84, N9.60. Found C67.90, H4.83, N9.58.
2.4.7. 5-Ethyl-2-{[4-(6-(1-phenyl)-2-(3,4-
dichlorobenzamidopyrimidin-4-yl)]phenoxyethyl} pyridine (6g)
m.p. 128–130 C. Yield 65%. Rf: 0.64. IR (KBr): t= 3063
(Ar-H), 2954, 2835 (–CH2–), 1677 (Amide-1), 1606 (–C‚N),
1534 (Amide-2), 1245 (Amide-3), 1223, 1033 (C–O–C). 1H
NMR (CDCl3, 400 MHz): d= 1.17 (t, 3H, –CH3), 2.35 (s,
3H, –CH3), 2.51 (q, 2H, –CH2), 3.18 (t, 2H, –CH2), 4.35 (t,
2H, –CH2–O), 7.00–8.18 (m, 11H, Ar-H), 7.35–8.31 (m, 3H,
Pyridine-H), 7.83 (s, 1H, Pyrimidine-H), 9.33 (s, 1H –NHCO);
13C NMR (100 MHz, CDCl3): d= 15.8 (C8), 21.4 (C37), 25.9
(C7), 37.3 (C9), 67.9 (C10), 103.4 (C22), 115.3–155.7 (C11–
C16), 123.0–160.5 (C2–C6), 127.1–144.0 (C24–C35), 161.2
(C21), 161.2 (C19), 163.6 (C17), 165.4 (C36), Anal. calcd for
C32H26N4O2Cl2: C67.49, H4.60, N9.84. Found C67.45,
H4.63, N9.82.
2.4.8. 5-Ethyl-2-{[4-(6-(4-ﬂuorophenyl)-2-(3,4-dichloro-
benzamidopyrimidin-4-yl)]phenoxy ethyl} pyridine (6h)
m.p. 190–192 C. Yield 63%. Rf: 0.68. IR (KBr): t= 3066
(Ar-H), 2956, 2838 (–CH2–), 1677 (Amide-1), 1608 (–C‚N),
1533 (Amide-2), 1250 (Amide-3), 1220, 1034 (C–O–C), 974
(C–F). 1H NMR (CDCl3, 400 MHz): d= 1.13(t, 3H, –CH3),
2.32 (s, 3H, –CH3), 2.52 (q, 2H, –CH2), 3.16 (t, 2H, –CH2),
4.34 (t, 2H, –CH2–O), 7.10–8.12 (m, 11H, Ar-H), 7.34–8.34
(m, 3H, Pyridine-H), 7.86 (s, 1H, Pyrimidine-H), 9.36 (s, 1H
–NHCO); 13C NMR (100 MHz, CDCl3): d= 15.3 (C8), 21.5
(C37), 25.4 (C7), 37.2 (C9), 67.5 (C10), 103.8 (C22), 115.2–
155.8 (C11–C16), 123.9–161.3 (C2–C6), 127.9–145.4 (C24–
C35), 161.4 (C21), 162.0 (C19), 163.9 (C17), 166.0 (C36), Anal.
calcd for C32H25N4O2Cl2F: C65.42, H4.29, N9.54. Found
C65.43, H4.25, N9.53.
2.4.9. 5-Ethyl-2-{[4-(6-(2,4-ﬂuorophenyl)-2-(3,4-
dichlorobenzamidopyrimidin-4-yl)]phenoxy ethyl} pyridine (6i)
m.p. 98–100 C. Yield, 71%. Rf: 0.62. IR (KBr): t= 3062 (Ar-
H), 2952, 2836 (–CH2–), 1676 (Amide-1), 1612 (–C‚N), 1536
(Amide-2), 1247 (Amide-3), 1224, 1034 (C–O–C), 976 (C–F).
1H NMR (CDCl3, 400 MHz): d= 1.14 (t, 3H, –CH3), 2.34
(s, 3H, –CH3), 2.55 (q, 2H, –CH2), 3.15 (t, 2H, –CH2), 4.31
(t, 2H, –CH2–O), 7.07–8.12 (m, 11H, Ar-H), 7.36–8.36 (m,
3H, Pyridine-H), 7.87 (s, 1H, Pyrimidine-H), 9.40 (s, 1H –
NHCO); 13C NMR (100 MHz, CDCl3): d= 15.2 (C8), 21.5
(C37), 25.3 (C7), 37.2 (C9), 67.0 (C10), 103.8 (C22), 115.0–
156.1 (C11–C16), 123.8–160.2 (C2–C6), 127.5–144.8 (C24–
C35), 161.3 (C21), 161.2 (C19), 163.6 (C17), 165.1 (C36), Anal.
calcd for C32H24N4O2Cl2F2: C63.48, H4.00, N9.25. Found
C63.45, H4.01, N9.23.
2.4.10. 5-Ethyl-2-{[4-(6-(4-bromophenyl)-2-(3,4-
dichlorobenzamidopyrimidin-4-yl)]phenoxy ethyl} pyridine (6j)
m.p. 183–184 C. Yield, 66%. Rf: 0.68. IR (KBr): t= 3065
(Ar-H), 2956, 2837(–CH2–), 1673 (Amide-1), 1604 (–C‚N),1536 (Amide-2), 1246 (Amide-3), 1222, 1037 (C–O–C), 858
(C–Br). 1H NMR (CDCl3, 400 MHz): d= 11.20 (t, 3H, –
CH3), 2.38 (s, 3H, –CH3), 2.50 (q, 2H, –CH2), 3.19 (t, 2H, –
CH2), 4.38 (t, 2H, –CH2–O), 7.15–8.20 (m, 11H, Ar-H),
7.37–8.36 (m, 3H, Pyridine-H), 7.82 (s, 1H, Pyrimidine-H),
9.32 (s, 1H –NHCO); 13C NMR (100 MHz, CDCl3):
d= 15.7 (C8), 21.6 (C37), 25.4 (C7), 37.4 (C9), 67.2 (C10),
104.0 (C22), 115.8–155.7 (C11–C16), 123.3–161.8 (C2–C6),
127.8–144.2 (C24–C35), 161.4 (C21), 161.2 (C19), 163.0
(C17), 165.6 (C36). Anal. calcd for C32H25N4O2Cl2Br:




m.p. 150–151 C. Yield 59%. Rf: 0.62. IR (KBr): t= 3068
(Ar-H), 2954, 2839 (–CH2–), 1675 (Amide-1), 1606 (–C‚N),
1535 (Amide-2), 1246 (Amide-3), 1227, 1034 (C–O–C), 750
(C–Cl). 1H NMR (CDCl3, 400 MHz): d= 1.19 (t, 3H, –
CH3), 2.33 (s, 3H, –CH3), 2.54 (q, 2H, –CH2), 3.14 (t, 2H, –
CH2), 4.34 (t, 2H, –CH2–O), 7.10–8.10 (m, 11H, Ar-H),
7.32–8.28 (m, 3H, Pyridine-H), 7.80 (s, 1H, Pyrimidine-H),
9.34 (s, 1H –NHCO); 13C NMR (100 MHz, CDCl3):
d= 15.1 (C8), 21.5 (C37), 25.8 (C7), 37.8 (C9), 67.6 (C10),
103.7 (C22), 115.3–155.6 (C11–C16), 123.8–160.6 (C2–C6),
127.5–145.0 (C24–C35), 161.3 (C21), 161.4 (C19), 163.8
(C17), 165.3 (C36). Anal. calcd for C32H24N4O2Cl4: C60.21,
H3.79, N8.78. Found C60.26, H3.74, N8.71.
2.4.12. 5-Ethyl-2-{[4-(6-(4-chlorophenyl)-2-(3,4-
dichlorobenzamidopyrimidin-4-yl)]phenoxy ethyl} pyridine (6l)
m.p. 163–165 C. Yield 62%. Rf: 0.64. IR (KBr): t= 3063
(Ar-H), 2955, 2834 (–CH2–), 1672 (Amide-1), 1611 (–C‚N),
1533 (Amide-2), 1243 (Amide-3), 1224, 1036 (C–O–C), 745
(C–Cl). 1H NMR (CDCl3, 400 MHz): d= 1.19 (t, 3H, –
CH3), 2.33 (s, 3H, –CH3), 2.54 (q, 2H, –CH2), 3.14 (t, 2H, –
CH2), 4.34 (t, 2H, –CH2–O), 7.10–8.10 (m, 11H, Ar-H),
7.32–8.28 (m, 3H, Pyridine-H), 7.80 (s, 1H, Pyrimidine-H),
9.34 (s, 1H –NHCO); 13C NMR (100 MHz, CDCl3):
d= 15.1 (C8), 21.5 (C37), 25.8 (C7), 37.8 (C9), 67.6 (C10),
103.7 (C22), 115.3–155.6 (C11–C16), 123.8–160.6 (C2–C6),
127.5–145.0 (C24–C35), 161.3 (C21), 161.4 (C19), 163.8
(C17), 165.3 (C36), Anal. calcd for C32H25N4O2Cl3: C63.64,




m.p. 95–96 C. Yield 67%, Rf: 0.66. IR (KBr): t= 3064 (Ar-
H), 2956, 2836 (–CH2–), 1673 (Amide-1), 1605 (–C‚N),
1536 (Amide-2), 1244 (Amide-3) 1221, 1034 (C–O–C). 1H
NMR (CDCl3, 400 MHz): d= 1.13 (t, 3H, –CH3), 2.30 (s,
3H, –CH3), 2.54 (q, 2H, –CH2), 3.16 (t, 2H, –CH2), 4.31 (t,
2H, –CH2–O), 7.05–8.17 (m, 11H, Ar-H), 7.34–8.33 (m, 3H,
Pyridine-H), 7.85 (s, 1H, Pyrimidine-H), 9.31 (s, 1H –NHCO);
13C NMR (100 MHz, CDCl3): d= 15.2 (C8), 25.6 (C7), 38.5
(C9), 55.7 (C30), 67.8 (C10), 103.2 (C22), 113.9–154.5 (C11–
C16), 114.9–160.0 (C24–C29), 123.1–160.5 (C2–C6), 160.1
(C21), 163.2 (C17), 164.3 (C19), Anal. calcd for
C33H28N4O3Cl2: C66.11, H4.71, N9.35; found C66.08,
H4.70, N9.34.
88 N.B. Patel, H.R. Patel2.4.14. 5-Ethyl-2-{[4-(6-(3-ﬂuorophenyl)-2-(3,4-
dichlorobenzamidopyrimidin-4-yl)]phenoxy ethyl} pyridine
(6n)
m.p. 98–100 C. Yield 65%, Rf: 0.61. IR (KBr): t= 3066 (Ar-
H), 2954, 2836 (–CH2–), 1675 (Amide-1), 1606 (–C‚N), 1536
(Amide-2), 1245 (Amide-3), 1224, 1036 (C–O–C), 977 (C–F).
1H NMR (CDCl3, 400 MHz): d= 1.21(t, 3H, –CH3), 2.32 (s,
3H, –CH3), 2.56(q, 2H, –CH2), 3.18(t, 2H, –CH2), 4.35(t,
2H, –CH2–O), 7.12–8.20 (m, 11H, Ar-H), 7.35–8.32 (m, 3H,
Pyridine-H), 7.86 (s, 1H, Pyrimidine-H), 9.32 (s, 1H –NHCO);
13C NMR (100 MHz, CDCl3): d= 15.6 (C8), 21.4 (C37), 25.9
(C7), 37.4 (C9), 67.3 (C10), 103.7 (C22), 115.3–155.4 (C11–
C16), 123.6–160.5 (C2–C6), 127.8–144.2 (C24–C35), 161.4
(C21), 161.4 (C19), 163.2 (C17), 165.2 (C36), Anal. calcd for





m.p. 178–180 C. Yield 67%, Rf: 0.65. IR (KBr): t= 3065
(Ar-H), 2953, 2835 (–CH2–), 1676 (Amide-1), 1610 (–C‚N),
1533 (Amide-2), 1246 (Amide-3), 1221, 1032 (C–O–C), 974
(C–F). 1H NMR (CDCl3, 400 MHz): d= 1.19 (t, 3H, –























Scheme 1 Synthesis of the compounds 4a–o, 5a–o and 6a–o. Rea
triethylamine; (B) 4-hydroxy benzaldehyde, ethanol, NaOH; (C) subst
sodium ethoxide, Ethanol; (E) 3,4-dichloro benzoyl choride, pyridine.CH2), 4.33 (t, 2H, –CH2–O), 7.11–8.16 (m, 11H, Ar-H),
7.34–8.31 (m, 3H, Pyridine-H), 7.87 (s, 1H, Pyrimidine-H),
9.34 (s, 1H –NHCO); 13C NMR (100 MHz, CDCl3):
d= 15.2 (C8), 21.5 (C37), 25.5 (C7), 37.3 (C9), 67.3 (C10),
103.3 (C22), 115.2–155.0 (C11–C16), 123.7–160.6 (C2–C6),
127.2–144.7 (C24–C35), 161.5 (C21), 161.4(C19), 163.5(C17),
165.5(C36), Anal. calcd for C32H24N4O2Cl2F2: C63.48,
H4.00, N9.25. Found C63.42, H4.02, N9.24.
3. Results and discussion
3.1. Chemistry
The synthesis of chalcones, pyrimidines and amide derivatives
is outlined in Scheme 1. First the chalcones (4a–o) were pre-
pared from 5-ethyl-2-[4-(carboxalehyde)phenoxyethyl]pyridine
with different substituted aromatic acetophenones in diluted
methanolic sodium hydroxide solution at room temperature.
The compounds (5a–o) were synthesized from different chal-
cones with guanidine nitrate and sodium hydroxide in metha-
nol. The compounds (6a–o) were prepared from different
pyrimidines and 3,4-dichloro benzoyl chloride. The purity of
the compounds was determined by TLC and elemental analysis
and all the synthesized heterocycles were conﬁrmed by 1H





















gents and conditions: (A) methane sulphonyl chloride, toluene,
ituted acetophenone, methanol, 2% NaOH; (D) guanidine nitrate,
Characterization and pharmacological evaluation of new pyridine analogs 89From the IR sharp band was observed at 1662 cm1 for –
C‚O and at 1599 cm1 for –CH‚CH– of chalcones 4a–o.
The 1H NMR spectra exhibited one doublet at d 7.11 attrib-
uted to the ‚CH–CO– protons. In the 13C NMR spectra of
chalcones, –CH‚CH– carbon appeared at the d 144.2 and
119.7 ppm, respectively. The higher ﬁeld resonances at d
190.0 ppm were attributed to the carbonyl group present inTable 1 Antimicrobial activity of compounds 4a–o, 5a–o and 6a–o
Comp. R Minimal bactericidal concentratio
Gram negative Gra
E. coli P. aeruginosa S. a
4a 2,4-Cl,5-F 200 250 100
4b 4-OCH3 100 150 250
4c 2,4-Cl 150 500 500
4d 4-OH 150 200 250
4e 2,6-Cl,5-F 500 250 500
4f 4-CH3 100 150 100
4g H 500 1000 100
4h 4-F 62.5 100 150
4i 2,4-F 250 250 500
4j 4-Br 500 500 500
4k 3,4-Cl 500 500 100
4l 4-Cl 500 250 500
4m 3-OCH3 500 500 100
4n 3-F 250 500 250
4o 3,4-F 125 250 500
5a 2,4-Cl,5-F 150 250 500
5b 4-OCH3 62.5 150 250
5c 2,4-Cl 500 500 250
5d 4-OH 250 200 500
5e 2,6-Cl,5-F 250 150 100
5f 4-CH3 200 200 250
5g H 250 250 500
5h 4-F 250 250 100
5i 2,4-F 62.5 150 150
5j 4-Br 250 250 200
5k 3,4-Cl 250 250 250
5l 4-Cl 250 100 150
5m 3-OCH3 250 250 500
5n 3-F 500 500 250
5o 3,4-F 250 500 500
6a 2,4-Cl,5-F 250 500 150
6b 4-OCH3 250 100 150
6c 2,4-Cl 500 250 250
6d 4-OH 250 200 500
6e 2,6-Cl,5-F 250 250 500
6f 4-CH3 200 250 250
6g H 500 1000 500
6h 4-F 150 200 500
6i 2,4-F 100 250 100
6j 4-Br 100 500 500
6k 3,4-Cl 500 250 500
6l 4-Cl 250 250 250
6m 3-OCH3 500 500 100
6n 3-F 500 500 100
6o 3,4-F 250 500 250
Gentamycin 0.05 1 0.25
Ampicillin 100 100 250
Chloroamphenicol 50 50 50
Ciproﬂoxacin 25 25 50
Norﬂoxacin 10 10 10
Nystatin – – –
Greseofulvin – – –chalcone. The structures of compounds 5a–o and 6a–o were
also established by using IR and NMR spectroscopy. The IR
of pyrimidine, disappearance of –C‚O band at 1662 cm1
and appearance of asymmetric and symmetric new broad
bands at 3355 cm1 and 3220 cm1 for –NH2, respectively. A
new signal was observed at d 5.15 and d 7.85 for the –NH2
and –CH in pyrimidine ring, respectively. From the 13C.
n lg/ml Minimal fungicidal concentration lg/ml
m positive
ureus S. pyogenus C. albicans A. niger A. clavatus
0 1000 1000 500 500
250 1000 1000 1000
500 500 500 1000
250 500 500 1000
1000 1000 500 500
250 1000 1000 1000
0 1000 200 500 500
150 250 >1000 >1000
500 1000 1000 1000
250 1000 >1000 >1000
0 1000 1000 >1000 >1000
250 1000 500 500
0 1000 500 500 500
500 500 1000 1000
500 1000 1000 1000
500 500 500 1000
250 500 >1000 >1000
500 500 >1000 >1000
500 500 500 1000
0 1000 500 500 500
250 500 500 500
500 500 500 500
100 500 250 250
200 500 1000 1000
200 1000 1000 1000
250 1000 500 500
250 500 500 500
500 1000 500 500
250 500 1000 1000
250 200 200 200
250 500 500 500
150 1000 500 500
250 1000 >1000 >1000
500 500 500 500
250 500 >1000 >1000
500 100 200 200
500 1000 500 500
500 500 1000 1000
100 500 500 500
500 1000 >1000 >1000
500 100 100 100
500 1000 500 500
0 1000 1000 1000 1000
0 500 500 1000 1000
250 >1000 >1000 >1000
0.5 – – –
100 – – –
50 – – –
50 – – –
10 – – –
– 100 100 100
– 500 100 100
90 N.B. Patel, H.R. PatelNMR, pyrimidine –CH carbon appeared at d 103.2. The three
bands were observed at 1672 cm1, 1537 cm
1 and 1250 cm1
of amide –C‚O, –NH– and C–N, respectively. Similarly the
disappearance of NH2 and the appearance of a signal at d
9.25 due to –NHCO provided further evidence for the conver-
sion of compound 5–6 and also 13C NMR spectra showing the
amide signal at d 165.3 ppm conﬁrmed this.
On the basis of the above-mentioned spectral data, com-
pounds 4a–o, 5a–o and 6a–o were conﬁrmed.
3.2. Antimicrobial activity
The MICs of synthesized compounds were carried out by
broth micro dilution method as described by Rattan (2000).
3.3. Antibacterial activity
The minimal bactericidal concentrations (MBCs) of the
tested compounds are shown in Table 1. The different com-
pounds 4a–o, 5a–o and 6a–o were tested in vitro against two
gram-positive (S. aureus MTCC 96, S. pyogenus MTCC 443)
and two-gram negative (E. coli MTCC 442, P. aeruginosa
MTCC 441) bacteria. From the screening data, most of the
compounds possessed very good antibacterial activity
(MBC, 50–250 lg/ml) against S. aureus; some of them
showed excellent activity with ampicillin. Chalcones 4b (4-
OCH3), 4f (4-CH3) and 4h (4-F) showed MBC in the range
between 62.5 and 100 lg/ml while ampicillin has MBC
100 lg/ml against E. coli which indicates that these com-
pounds have excellent activity, while other chalcones 4c
(2,4-Cl), 4d (4-OH) and 4o (3,4-F) possessed MBC 125–
150 lg/ml against E. coli and 4h (4-F) exhibited very good
activity against P. aeruginosa. Compounds 4f (4-CH3) and
4h (4-F) displayed excellent activity in the range of 100–
150 lg/ml while remaining 4b (4-OCH3), 4d (4-OH) and 4n
(3-F) were comparable against S. aureus with ampicillin.
Compound 4h (4-F) has MBC 150 lg/ml which was compar-
atively good against S. pyogenus. The remaining chalcones
possessed moderate to poor activity against all four bacterial
species. For pyrimidines, 5b (4-OCH3) possessed MBC
62.5 lg/ml against E. coli and MBC 150 lg/ml against P.
aeruginosa comparable with ampicillin. Compound 5e (2,6-
Cl,5-F) exhibited MBC 150 lg/ml against P. aeruginosa.
Compound 5h (4-F) possessed MBC 100 lg/ml against S.
aureus and S. pyogeneus. Compound 5i (2,4-F) possessed
MBC 62.5 lg/ml against E. coli and MBC 150 lg/ml against
S. aureus and showed good activity as that of ampicillin.
Compound 5l (4-Cl) showed MBC 100 lg/ml against P. aeru-
ginosa and MBC 150 lg/ml against S. aureus. Other pyrimi-
dines displayed moderate to poor activities against all four
bacterial species. Amides 6i (2,4-F) and 6j (4-Br) showed
MBC 100 lg/ml against E. coli which is same as ampicillin.
Compound 6b (4-OCH3) showed MBC 100 lg/ml against
P. aeruginosa; comparable with ampicillin. Compounds 6a
(2,4-Cl, 5-F), 6b (4-OCH3) and 6i (2,4-F) showed MBC
100–150 lg/ml against S. aureus while ampicillin itself
showed MBC 250 lg/ml which indicates that these com-
pounds are highly active. Compound 6i (2,4-F) showed
MBC 100–150 lg/ml against S. pyogeneus. Remaining amides
possessed moderate to poor activities against all four bacte-
rial species.3.4. Antifungal activity
Minimal fungicidal concentrations (MFCs) of the synthesized
compounds are shown in Table 1. For in vitro antifungal activ-
ity, three fungal species C. albicans MTCC 227, A. niger
MTCC 282 and A. clavatus MTCC 1323 were used and com-
pared with the standard drug greseofulvin. Chalcones 4g (–
H) and 4h (4-F) showed excellent activity of 200–250 lg/ml;
4c (2,4-Cl), 4d (4-OH), 4m (3-OCH3) and 4n (3-F) possessed
very good activity of 500 lg/ml with greseofulvin (500 lg/ml)
against C. albicans whereas chalcones possessed moderate to
poor activity against A. niger and A. clavatus. Pyrimidines 5o
(3,4-F) possessed good activity of 200 lg/ml against C. albi-
cans, which is comparable with greseofulvin (500 lg/ml).
Amides 6f (4-CH3) and 6k (3,4-Cl) displayed excellent activity
of 100 lg/ml against C. albicans and comparable with greseo-
fulvin and nystatin. Compound 6k (3,4-Cl) possessed very
good activity of 100 lg/ml against A. niger and A. clavatus.
From the antifungal results it can be concluded that com-
pound 6k (3,4-Cl) is very active like the standard drugs.
4. Conclusions
Chalcones 4b, 4f and 4h are found to be excellent against all
bacteria; where as pyrimidines 5b and 5i are very effective
and comparable with the standard drug. Amides 6i, 6j, 6b
and 6a are more active and are comparable with the standard
drugs.
Antifungal activities of chalcones 4g and 4h are more effec-
tive against all three fungal species. For pyrimidines, 5o was
found comparable against C. albicans, while amides 6f and
6k are more effective against three fungal species. These results
make new chalcone, pyrimidine and amide derivatives interest-
ing for further synthetic and biological evaluation.Acknowledgements
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